DEA Places Brexanolone Into Schedule IV
The Drug Enforcement Administration placed the neurosteroid brexanolone into Schedule IV of the Controlled Substances Act, it said. The final rule confirms an interim regulation issued in June that subjected brexanolone to new registration, labeling, recordkeeping, and import and export requirements.
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
(Federal Register 01/24/20)